NCT00135200 2025-04-30
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
University of Michigan Rogel Cancer Center
Phase 2 Completed
Clinical Trials
9 trialsNCT00479167 2021-11-04
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Rush University Medical Center
Phase 2 Terminated
NCT00476047 2017-10-12
Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00073918 2017-08-18
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00577629 2017-05-30
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Duke University
Phase 2 Completed
NCT00490009 2017-03-30
Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
Stanford University
Phase 2 Completed
NCT00490490 2017-03-29
Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy
Stanford University
Phase 2 Terminated
NCT01389076 2017-01-30
Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT00475332 2012-02-15
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
University of Florida
Phase 2 Terminated